<DOC>
	<DOCNO>NCT01135511</DOCNO>
	<brief_summary>The purpose study evaluate dose-response , efficacy safety CP-690,550 eye drop patient dry eye disease .</brief_summary>
	<brief_title>A Phase II , Dose Ranging Study Of CP-690,550 Eye Drops In Patients With Dry Eye Disease</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Subjective symptom dry eye least 6 month Signs moderate severe dry eye ( corneal stain score schirmer test without anesthesia ) Women nursing , pregnant planning pregnancy study Participation study within 30 day screen visit Ocular disorder may confound interpretation study result</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Dry eye</keyword>
</DOC>